Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Where Will Amgen Be in 5 Years?


Biotech companies must develop new medicines to remain successful since older ones eventually encounter patent cliffs and face generic or biosimilar competition. However, launching new drugs is no guarantee of success. Many therapies aren't nearly as successful as hoped.

Biotech giant (NASDAQ: AMGN) has had a harsh reminder of that reality in recent years. Some of its most recent brand-new launches, especially the cancer drug Lumakras, have made paltry (at best) contributions to its top line, while some of its legacy products are racking up declining sales.

Amgen does have a plan to turn things around, though. Can the drugmaker be successful? Let's find out how things could evolve for the company through the next half-decade.

Continue reading


Source Fool.com

Amgen Inc. Stock

€253.10
0.160%
The Amgen Inc. stock is trending slightly upwards today, with an increase of €0.40 (0.160%) compared to yesterday's price.
With 27 Buy predictions and 3 Sell predictions Amgen Inc. is one of the favorites of our community.
As a result the target price of 318 € shows a positive potential of 25.64% compared to the current price of 253.1 € for Amgen Inc..
Like: 0
Share

Comments